Key facts
- Notable investors include Brabantse Ontwikkelings Maatschappij, Libertatis Ergo Holding (LEH), unlock_.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Cantoni Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Cantoni Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cantoni Therapeutics
Developer of small-molecule therapeutics designed for the inhibition of nicotinamide N-methyltransferase (NNMT) to address cardiometabolic diseases and related conditions. The company's platform includes bisubstrate NNMT inhibitors that bind both SAM and NA active sites with high potency and reduced substrate dependency, enabling clients to target underlying metabolic dysfunctions such as insulin resistance, obesity, and type 2 diabetes with improved efficacy over traditional substrate-competitive compounds.
- Sector
- Healthcare
- HQ
- Oss, Netherlands
- Founded
- 2022
- Website
- cantonitx.nl/
- Ownership
- Privately Held (backing)
Cantoni Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cantoni Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cantoni Therapeutics in its N-PORT filings yet. We sweep new filings monthly.